Indee Labs

Indee Labs develops a non-viral Hydropore technology to rapidly deliver molecules and editing complexes into immune cells, enabling accelerated discovery, development, and manufacturing of engineered cell therapies such as T-cell immunotherapies.

Hydropore is a non-viral platform that utilizes microfluidic vortex shedding (µVS) to deliver small molecules, nucleic acids, proteins, and gene-editing complexes into immune cells. The process is described as simple, scalable, and capable of yielding millions to billions of high-quality cells while preserving viability and function. It bypasses viral transduction and traditional electroporation, supports high-throughput screening, is developed in a regulatory-ready manner, and materials in the flow path are medical-grade. The system is available for Research Use Only, with a clinical system regulated as a tool for biologics manufacturing.

Who it’s for: Biotech and pharma companies focused on T-cell immunotherapies, cell therapy discovery, development, and manufacturing, including researchers and contract manufacturers seeking non-viral cell engineering tools.

Company news and partnerships; product availability for RUO; multiple press releases and collaborations indicating active commercialization and industry engagement